Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100065022 | 10006502 | 2 | F | 2012 | 20140318 | 20140313 | 20140331 | EXP | CN-SA-2014SA028107 | AVENTIS | 57.00 | YR | F | Y | 65.00000 | KG | 20140331 | N | CN | CN | CN |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100065022 | 10006502 | 1 | PS | COAPROVEL | 1 | ORAL | D | UNKNOWN | 20758 | 150 | MG | TABLET | QD | ||||||
| 100065022 | 10006502 | 2 | C | PLENDIL | 1 | ORAL | D | 0 | 5 | MG | PROLONGED-RELEASE TABLET | QD | |||||||
| 100065022 | 10006502 | 3 | C | EUTHYROX | 1 | ORAL | ABOUT 7 OR 8 YEARS AGO | D | 0 | 75 | UG | TABLET | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 100065022 | 10006502 | 1 | Hypertension |
| 100065022 | 10006502 | 2 | Hypertension |
| 100065022 | 10006502 | 3 | Hyperthyroidism |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 100065022 | 10006502 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 100065022 | 10006502 | Gout | |
| 100065022 | 10006502 | Nephrolithiasis |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 100065022 | 10006502 | 1 | 2011 | 0 | ||
| 100065022 | 10006502 | 2 | 2011 | 0 |